FDA
-
-
-
-
-
-
-
Jaguar Health signs $38 million license deal with Future Pak
-
-
-
-
-
-
-
FDA extends approval for Jaguar Health's dog diarrhea drug through 2026
-
-
-
-
-
-
-
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Cli
-
-
-
-
-
-
-
FDA authorizes expanded access programs for Jaguar Health crofelemer
-
-
-
-
-
-
-
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
-
-
-
-
-
-
-
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
-
-
-
-
-
-
-
Jaguar Health (JAGX) Announces Extension of the Maturity Date of its Convertible Promissory Notes
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
